Published on in Vol 7, No 7 (2018): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Isao Hara 1, MD, PhD;  Shimpei Yamashita 1, MD;  Satoshi Nishizawa 1, MD, Ph D;  Kazuro Kikkawa 1, MD, PhD;  Toshio Shimokawa 2, PhD;  Yasuo Kohjimoto 1, MD, PhD

1 Department of Urology, Wakayama Medical University , Wakayama , JP

2 Clinical Research Center, Wakayama Medical University , Wakayama , JP

Corresponding Author: